Geode Capital Management
BSTG

Geode Capital Management’s Biostage, Inc. Common Stock BSTG Stock Holding History

Geode Capital Management’s Portfolio BSTG Stock Details BSTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-26,101
Closed -$8K – 4109
2017
Q3 		$8K Hold
26,101
– – ﹤0.01% 4046
2017
Q2 		$10K Sell
26,101
-1,453
-5% -$462 ﹤0.01% 4075
2017
Q1 		$10K Buy
27,554
+198
+0.7% +$108 ﹤0.01% 4060
2016
Q4 		$24K Buy
27,356
+132
+0.5% +$118 ﹤0.01% 3988
2016
Q3 		$29K Buy
27,224
+33
+0.1% +$36 ﹤0.01% 3973
2016
Q2 		$30K Hold
27,191
– – ﹤0.01% 3993
2016
Q1 		$48.9K Sell
27,191
-33
-0.1% -$55 0.03% 538
2015
Q4 		$59K Buy
27,224
+66
+0.2% +$92 ﹤0.01% 3979
2015
Q3 		$23K Buy
27,158
+40
+0.1% +$45 ﹤0.01% 4084
2015
Q2 		$38K Buy
27,118
+33
+0.1% +$81 ﹤0.01% 3889
2015
Q1 		$88K Buy
27,085
+99
+0.4% +$337 ﹤0.01% 3776
2014
Q4 		$85K Buy
26,986
+99
+0.4% +$490 ﹤0.01% 3814
2014
Q3 		$217K Buy
26,887
+6,598
+33% +$54K ﹤0.01% 3544
2014
Q2 		$212K Sell
20,289
-3,533
-15% -$30.1K ﹤0.01% 3503
2014
Q1 		$216K Buy
23,822
+1,209
+5% +$7.17K ﹤0.01% 3472
2013
Q4 		$107K Buy
+22,613
New +$106K ﹤0.01% 3586

Geode Capital Management's BSTG Position: Q4 2017 in Review

Geode Capital Management sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2017, closing a stake of 26,101 shares — an estimated $8K sold.

Geode Capital Management first reported a position in BSTG in Q4 2013 and held it in 16 quarters. The position peaked at $217K in Q3 2014. 0 funds tracked by Wall St. Rank hold BSTG as of Q4 2017.

  • Geode Capital Management reported no remaining Biostage, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Geode Capital Management sold 26,101 Biostage, Inc. Common Stock shares in Q4 2017, an estimated $8K.
  • Geode Capital Management first reported a position in Biostage, Inc. Common Stock in Q4 2013 and held it in 16 quarters.
  • Geode Capital Management's Biostage, Inc. Common Stock position peaked at $217K in Q3 2014.
  • 0 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2017.

Based on Geode Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.